Macrovascular Malignant Portal Vein Thrombosis in Cirrhotic Patients with HCC

@inproceedings{Shabana2016MacrovascularMP,
  title={Macrovascular Malignant Portal Vein Thrombosis in Cirrhotic Patients with HCC},
  author={Hany R. Shabana and Ehab E Abdel-Khalek and Alaa E. Elgamal and Mohammed Amin Mohammed and Talal Amer and Ahmed M Abdel-Khalek and Rizk E. Elbaz and Marwa S. Askar},
  year={2016}
}
1.1.    Background: The presence of macrovascular malignant portal vein thrombosis (MMPVT) in patients with HCC is one of the most significant prognostic factors. Without treatment, the survival is less than 3 months [1]. Standard treatment regimens have not been established in these patients. 1.2.    Aims: Our aim was to explore the prevalence and degrees of MMPVT in cirrhotic patients with HCC. Also, we aimed at determination of a correlation between the degree of MMPVT and both the tumour… 
3 Citations
Risk factors of malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma
TLDR
High Model For End-stage Liver Disease score, low serum albumin and raised α-fetoprotein are major risk factors for malignant PVT in cirrhotic patients with HCC, and HCC with malignant DVT is associated with other comorbidities, high rates of hospital admission, larger tumor size and more recurrent tumors.
Tumor multifocality and serum albumin levels can identify groups of patients with hepatocellular carcinoma and portal vein thrombosis having distinct survival outcomes
TLDR
Combination low tumor focality and high serum albumin identifies prognostically better PVT patient subgroups that might benefit from aggressive therapies.
Macrovascular Malignant Portal Vein Thrombosis in Cirrhotic Patients with HCC
TLDR
MMPVT of different degrees was present in 26% of cirrhotic HCC cases, associated with tumor burden, aggressiveness and degree of liver function impairment and there was a significant positive correlation between the grade of MMPVT and CTP score and tumor size.

References

SHOWING 1-10 OF 10 REFERENCES
Prognostic Index for Portal Vein Tumor Thrombosis in Patients with Hepatocellular Carcinoma Treated with Radiation Therapy
TLDR
The PITH scoring model, proposed in the current study in HCC patients with PVTT, reliably predict overall survival and correlated well with overall survival.
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation
  • F. Piscaglia, A. Gianstefani, +7 authors L. Bolondi
  • Medicine
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2010
TLDR
In conclusion, for a patient with HCC and portal vein thrombosis, appropriate investigations can establish whether the thromBosis is benign; patients with H CC and benign portal vein ThROMbosis are candidates for liver transplantation.
Prognostic index for patients with hepatocellular carcinoma combined with tumor thrombosis in the major portal vein.
TLDR
This prognostic index is a useful for making appropriate treatment strategy decisions for patients with hepatocellular carcinoma and tumor thrombosis in the major portal vein.
The incidence of portal vein thrombosis at liver transplantation
TLDR
The incidence of portal vein thrombosis was highest in the patients with hepatic malignancy in the cirrhotic liver, followed by those with Budd‐Chiari syndrome, and postnecrotic cirrhosis of various causes, which was significantly higher than that of those without shunt.
Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials
TLDR
The outcome of nonsurgical HCC is not homogeneously grim and may be predicted by assessing the presence of symptoms and of an invasive tumoral pattern and Therapeutic trials should be designed and evaluated considering these characteristics.
Liver Cancer Working Group report.
  • M. Kudo, Kwang Hyub Han, +7 authors M. Sakamoto
  • Medicine
    Japanese journal of clinical oncology
  • 2010
TLDR
Hepatocellular carcinoma is a highly prevalent disease in many Asian countries and long-term outcomes following treatment of even early/intermediate or advanced disease are often unsatisfactory because of a lack of effective adjuvant and systemic therapies.
Management of hepatocellular carcinoma: An update
Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged
Macrovascular Malignant Portal Vein Thrombosis in Cirrhotic Patients with HCC
TLDR
MMPVT of different degrees was present in 26% of cirrhotic HCC cases, associated with tumor burden, aggressiveness and degree of liver function impairment and there was a significant positive correlation between the grade of MMPVT and CTP score and tumor size.
Primary carcinoma of the liver. A study
  • Gastroenterol Hepatol Open Access
  • 1954